The purpose of this clinical trial is to evaluate the efficacy and safety of combined recanalization therapy in patients who cannot be recanalized by acute large vessel occlusive stroke. The main questions it aims to answer are: 1、Proportion of subjects with mRs score of 0-1 at 90 days after surgery Participants will: 1、In acute large vessel occlusive stroke, if traditional means cannot be recanalized, combined recanalization surgery (including arteriotomy and thrombectomy, cerebrovascular bypass surgery) is performed.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
64
Recombined recanalization surgery
Tianjin Huahu Hospital
Tianjin, Tianjin Municipality, China
RECRUITINGProportion of subjects with mRs score of 0-1 at 90 days after surgery
Time frame: 90 days after recombined recanalization surgery
Changes in NIHSS score at 24 hours after surgery, 7 days after surgery, 30 days after surgery and 90 days after surgery compared with baseline;
Time frame: 90 days after recombined recanalization surgery
The mRs score changed from baseline at 90 days after surgery
Time frame: 90 days after recombined recanalization surgery
Change from baseline in MOCA score at 90 days after surgery
Time frame: 90 days after recombined recanalization surgery
Change from baseline in MMSE score at 90 days after surgery
Time frame: 90 days after recombined recanalization surgery
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.